Alexandra Langlais

2.6k total citations
57 papers, 531 citations indexed

About

Alexandra Langlais is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Sociology and Political Science. According to data from OpenAlex, Alexandra Langlais has authored 57 papers receiving a total of 531 indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Pulmonary and Respiratory Medicine, 31 papers in Oncology and 7 papers in Sociology and Political Science. Recurrent topics in Alexandra Langlais's work include Lung Cancer Treatments and Mutations (29 papers), Lung Cancer Research Studies (16 papers) and Cancer Immunotherapy and Biomarkers (11 papers). Alexandra Langlais is often cited by papers focused on Lung Cancer Treatments and Mutations (29 papers), Lung Cancer Research Studies (16 papers) and Cancer Immunotherapy and Biomarkers (11 papers). Alexandra Langlais collaborates with scholars based in France, United States and South Africa. Alexandra Langlais's co-authors include Franck Morin, Julien Mazières, Denis Moro‐Sibilot, Gérard Zalcman, Olivier Molinier, Virginie Westeel, Fabrice Barlési, Clarisse Audigier-Valette, A. Lavolé and Thomas Egenod and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and British Journal of Cancer.

In The Last Decade

Alexandra Langlais

48 papers receiving 527 citations

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Alexandra Langlais	373	363	96	87	46	57	531
Pablo Lee	225 0.6×	270 0.7×	123 1.3×	66 0.8×	15 0.3×	21	432
Sami I. Bashour	199 0.5×	179 0.5×	100 1.0×	55 0.6×	45 1.0×	17	352
Mattias Bergqvist	217 0.6×	229 0.6×	117 1.2×	88 1.0×	15 0.3×	32	367
Lori Dowell	222 0.6×	189 0.5×	215 2.2×	81 0.9×	21 0.5×	7	390
Irene Rainville	198 0.5×	138 0.4×	158 1.6×	146 1.7×	18 0.4×	22	423
Theresia Wilbertz	229 0.6×	155 0.4×	310 3.2×	130 1.5×	22 0.5×	8	466
Laura Schubert	282 0.8×	199 0.5×	198 2.1×	156 1.8×	10 0.2×	13	397
Nobuhiko Nishijima	143 0.4×	110 0.3×	133 1.4×	79 0.9×	22 0.5×	15	302
Carolien Boeckx	109 0.3×	225 0.6×	155 1.6×	99 1.1×	13 0.3×	15	374
Victoria Heredia-Soto	83 0.2×	176 0.5×	158 1.6×	124 1.4×	32 0.7×	37	436

Countries citing papers authored by Alexandra Langlais

Since Specialization

Citations

This map shows the geographic impact of Alexandra Langlais's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alexandra Langlais with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alexandra Langlais more than expected).

Fields of papers citing papers by Alexandra Langlais

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alexandra Langlais. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alexandra Langlais. The network helps show where Alexandra Langlais may publish in the future.

Co-authorship network of co-authors of Alexandra Langlais

This figure shows the co-authorship network connecting the top 25 collaborators of Alexandra Langlais. A scholar is included among the top collaborators of Alexandra Langlais based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alexandra Langlais. Alexandra Langlais is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Tosato, Giovanna, Yuna Blum, Alexandra Langlais, et al.. (2025). 239MO: Stratification of pleural mesothelioma patients for combined immunotherapy based on sarcomatoid component and tumour microenvironment markers in the IFCT-MAPS2 study. Journal of Thoracic Oncology. 20(3). S151–S151. 1 indexed citations

Garinet, Simon, Caroline Léger, Fabrice Barlési, et al.. (2024). STK11/LKB1 alterations worsen the poor prognosis of KRAS mutated early-stage non-squamous non-small cell lung carcinoma, results based on the phase 2 IFCT TASTE trial. Lung Cancer. 190. 107508–107508. 2 indexed citations

Langlais, Alexandra. (2023). The new Common Agricultural Policy: reflecting an agro-ecological transition. The legal perspective. PubMed. 104(1). 51–66. 8 indexed citations

Zalcman, Gérard, Olivier Molinier, C. Dayen, et al.. (2022). 972O Nivolumab (Nivo) plus ipilimumab (Ipi) 6-months treatment versus continuation in patients with advanced non-small cell lung cancer (aNSCLC): Results of the randomized IFCT-1701 phase III trial. Annals of Oncology. 33. S992–S992. 7 indexed citations

Lavolé, A., Julien Mazières, S. Schneider, et al.. (2021). Assessment of nivolumab in HIV-Infected patients with advanced non-small cell lung cancer after prior chemotherapy. The IFCT-1602 CHIVA2 phase 2 clinical trial. Lung Cancer. 158. 146–150. 13 indexed citations

Wislez, Marie, Charlotte Domblides, Laurent Greillier, et al.. (2021). Circulating tumor DNA in advanced non-small-cell lung cancer patients with HIV is associated with shorter overall survival: Results from a Phase II trial (IFCT-1001 CHIVA). Lung Cancer. 157. 124–130. 5 indexed citations

Girard, Nicolas, Julien Mazières, Josiane Otto, et al.. (2021). LBA41 Nivolumab (nivo) ± ipilimumab (ipi) in pre-treated patients with advanced, refractory pulmonary or gastroenteropancreatic poorly differentiated neuroendocrine tumors (NECs) (GCO-001 NIPINEC). Annals of Oncology. 32. S1318–S1318. 19 indexed citations

Blons, Hélène, Jean‐Philippe Merlio, D. Debieuvre, et al.. (2020). PTEN, ATM, IDH1 mutations and MAPK pathway activation as modulators of PFS and OS in patients treated by first line EGFR TKI, an ancillary study of the French Cooperative Thoracic Intergroup (IFCT) Biomarkers France project. Lung Cancer. 151. 69–75. 7 indexed citations

Wislez, Marie, Julien Mazières, A. Lavolé, et al.. (2020). 1214O Neoadjuvant durvalumab in resectable non-small cell lung cancer (NSCLC): Preliminary results from a multicenter study (IFCT-1601 IONESCO). Annals of Oncology. 31. S794–S794. 40 indexed citations

10.

Baldacci, Simon, Benjamin Besse, Virginie Avrillon, et al.. (2020). 1303P Lorlatinib for advanced ALK+ non-small cell lung cancer (NSCLC): Efficacy and safety data from IFCT-1803 LORLATU expanded access program (EAP) cohort. Annals of Oncology. 31. S843–S843. 1 indexed citations

11.

Langlais, Alexandra, et al.. (2019). Sélection thématique de livres. Natures Sciences Sociétés. 27(1). 121–122.

12.

Langlais, Alexandra. (2019). L'agriculture et les paiements pour services environnementaux. Quels questionnements juridiques ?. HAL (Le Centre pour la Communication Scientifique Directe). 4 indexed citations

13.

Quoix, Élisabeth, Clarisse Audigier-Valette, A. Lavolé, et al.. (2018). Maintenance chemotherapy versus follow-up after carboplatin and weekly paclitaxel doublet chemotherapy in elderly patients with advanced non-small cell lung cancer (NSCLC): IFCT-1201 MODEL randomised phase III trial. Annals of Oncology. 29. viii744–viii745.

14.

Leduc, Charlotte, J.P. Merlio, Benjamin Besse, et al.. (2017). Clinical and molecular characteristics of non-small-cell lung cancer (NSCLC) harboring EGFR mutation: results of the nationwide French Cooperative Thoracic Intergroup (IFCT) program. Annals of Oncology. 28(11). 2715–2724. 66 indexed citations

15.

Guibert, Nicolas, Fabrice Barlési, R. Descourt, et al.. (2017). Characteristics and Outcomes of Patients with Lung Cancer Harboring Multiple Molecular Alterations: Results from the IFCT Study Biomarkers France. Journal of Thoracic Oncology. 12(6). 963–973. 44 indexed citations

16.

Guibert, Nicolas, Fabrice Barlési, R. Descourt, et al.. (2017). OA10.06 Characteristics and Outcomes of Patients with Lung Cancer Harboring Multiple Molecular Alterations (Biomarker IFCT Study). Journal of Thoracic Oncology. 12(1). S283–S283. 1 indexed citations

17.

Leduc, Charlotte, Erwan Pencreach, J.P. Merlio, et al.. (2017). Ultrasensitive detection of EGFR T790M mutation by droplet digital PCR (ddPCR) in TKI naïve non-small cell lung cancer (NSCLC) harboring EGFR mutation: Results of the nationwide program Biomarkers France of the French Cooperative Thoracic Intergroup (IFCT). Annals of Oncology. 28. v22–v23.

18.

Leduc, Charlotte, Hélène Blons, Benjamin Besse, et al.. (2016). Clinical and biological characteristics of non-small cell lung cancer (NSCLC) harbouring EGFR mutation: Results of the nationwide programme of the French Cooperative Thoracic Intergroup (IFCT). Annals of Oncology. 27. vi416–vi416. 2 indexed citations

19.

Walter, Christian, Antonio Bispo, Claire Chenu, Alexandra Langlais, & Christophe Schwartz. (2015). Les services écosystémiques des sols : du concept à sa valorisation. HAL (Le Centre pour la Communication Scientifique Directe). 53–68. 1 indexed citations

20.

Langlais, Alexandra. (2013). Les paiements pour services environnementaux, une nouvelle forme d'équité environnementale pour les agriculteurs ? . Réflexions juridiques. HAL (Le Centre pour la Communication Scientifique Directe). 18–27.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact